|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
SCIDIR_on1013889108 |
003 |
OCoLC |
005 |
20231120010237.0 |
006 |
m o d |
007 |
cr cnu|||unuuu |
008 |
171204s2018 enka ob 001 0 eng d |
040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d OCLCF
|d OPELS
|d UAB
|d IDEBK
|d D6H
|d CASUM
|d OCLCO
|d OCLCQ
|d MERER
|d ESU
|d U3W
|d OCLCQ
|d LVT
|d LQU
|d TSC
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCO
|d K6U
|d OCL
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 1031871742
|a 1031928825
|a 1105181812
|a 1105574981
|a 1176438784
|a 1229763590
|
020 |
|
|
|a 9780128136300
|q (electronic bk.)
|
020 |
|
|
|a 0128136308
|q (electronic bk.)
|
020 |
|
|
|z 9780128136294
|
020 |
|
|
|z 0128136294
|
035 |
|
|
|a (OCoLC)1013889108
|z (OCoLC)1031871742
|z (OCoLC)1031928825
|z (OCoLC)1105181812
|z (OCoLC)1105574981
|z (OCoLC)1176438784
|z (OCoLC)1229763590
|
050 |
|
4 |
|a RS192
|
072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
082 |
0 |
4 |
|a 615.1/9
|2 23
|
245 |
0 |
0 |
|a Nanoscale fabrication, optimization, scale-up and biological aspects of pharmaceutical nanotechnology /
|c edited by Alexan Mihai Grumezescu.
|
264 |
|
1 |
|a Kidlington, Oxford :
|b William Andrew, an imprint of Elsevier,
|c [2018]
|
264 |
|
4 |
|c �2018
|
300 |
|
|
|a 1 online resource :
|b illustrations
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Pharmaceutical nanotechnology series
|
504 |
|
|
|a Includes bibliographical references and index.
|
588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed December, 08, 2017).
|
520 |
|
|
|a Nanoscale Fabrication, Optimization, Scale-up and Biological Aspects of Pharmaceutical Nanotechnology focuses on the fabrication, optimization, scale-up and biological aspects of pharmaceutical nanotechnology. In particular, the following aspects of nanoparticle preparation methods are discussed: the need for less toxic reagents, simplification of the procedure to allow economic scale-up, and optimization to improve yield and entrapment efficiency. Written by a diverse range of international researchers, the chapters examine characterization and manufacturing of nanomaterials for pharmaceutical applications. Regulatory and policy aspects are also discussed. This book is a valuable reference resource for researchers in both academia and the pharmaceutical industry who want to learn more about how nanomaterials can best be utilized.
|
505 |
0 |
|
|a 1. Fabrication of polymeric core-shell nanostructures -- 2. Emulsification-diffusion method to obtain polymeric nanoparticles: two decades of research -- 3. Tools and Techniques for the optimized synthesis, reproducibility and scale up of desired nanostructures from plant derived material and their role in pharmaceutical properties -- 4. Scale up of biopharmaceuticals production -- 5. Physicochemical and morphological characterization of pharmaceutical nanocarriers and mathematical modelling of drug encapsulation/release mass transfer processes -- 6. Biopharmaceutics and pharmacokinetics of multifunctional nanoparticles -- 7. Technological delivery systems to improve biopharmaceutical properties -- 8. From physicochemically stable nanocarriers to targeted drug delivery: in-vivo pharmacokinetic, pharmacodynamic and biodistribution studies -- 9. Sterile dosage forms loaded nanosystems for parenteral, nasal, pulmonary and ocular administration -- 10. Quantitative Characterization of Targeted Nanoparticulate Formulations for Prediction of Clinical Efficacy -- 11. Analytical tools for reliable in vitro and in vivo performance testing of drug nanocrystals -- 12. Application of one-step affinity purification of drug-binding proteins with practical magnetic nanoparticles to drug discovery -- 13. Molecularly Imprinted Polymers as Separation Tools -- 14. Detection of DNA damage induced by nanomaterials -- 15. Pharmacological usage of an enzyme inhibitor -- a selective inhibitor of 3-mercaptopyruvate sulfurtransferase reaction intermediate to control generation of polysulfide -- 16. Regulatory Consideration in Nanotechnology Based Drug Products.
|
650 |
|
0 |
|a Pharmaceutical technology.
|
650 |
|
0 |
|a Nanobiotechnology.
|
650 |
|
0 |
|a Nanomedicine.
|
650 |
|
0 |
|a Nanotechnology.
|
650 |
1 |
2 |
|a Nanomedicine
|0 (DNLM)D050997
|
650 |
1 |
2 |
|a Technology, Pharmaceutical
|0 (DNLM)D013678
|
650 |
2 |
2 |
|a Nanostructures
|0 (DNLM)D049329
|
650 |
|
2 |
|a Nanotechnology
|0 (DNLM)D036103
|
650 |
|
6 |
|a Techniques pharmaceutiques.
|0 (CaQQLa)201-0138380
|
650 |
|
6 |
|a Nanobiotechnologie.
|0 (CaQQLa)000286131
|
650 |
|
6 |
|a Nanom�edecine.
|0 (CaQQLa)201-0448752
|
650 |
|
6 |
|a Nanotechnologie.
|0 (CaQQLa)201-0225435
|
650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a Nanotechnology
|2 fast
|0 (OCoLC)fst01032639
|
650 |
|
7 |
|a Nanobiotechnology
|2 fast
|0 (OCoLC)fst01894713
|
650 |
|
7 |
|a Nanomedicine
|2 fast
|0 (OCoLC)fst01744350
|
650 |
|
7 |
|a Pharmaceutical technology
|2 fast
|0 (OCoLC)fst01060211
|
655 |
|
4 |
|a Internet Resources.
|
700 |
1 |
|
|a Grumezescu, Alexandru Mihai,
|e editor.
|
830 |
|
0 |
|a Pharmaceutical nanotechnology series.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128136294
|z Texto completo
|